Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Bio-Thera Approved to Launch Humira Biosimilar in China

publication date: Nov 7, 2019

Bio-Thera Solutions of Guangzhou was approved for a China launch of Qletli® (格乐立®), its biosimilar to autoimmune disease treatment Humira, the world's best selling drug. Qletli, the first Humira biosimilar approved in China, will be indicated for the same three conditions as the original drug: rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis. Bio-Thera develops biosimilars and novel drugs for cancer, autoimmune and cardiovascular diseases. The company will also seek approvals for Qletli in other markets. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China